TriangleHEALTH PROFESSIONAL · SOURCE READING
FCR
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
FCR is used for patients with an IGH hypermutation.
Evidence (FCR):
Several trials used FCR for appropriate patients with IGH pathogenic variants who required therapy.
Several trials used FCR for appropriate patients with IGH pathogenic variants who required therapy.
The PFS rate exceeded 60% at more than 10 years.[24-26][Level of evidence C2] Nonetheless, late relapses were seen beyond 10 years.
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice